The MDM2-p53 piperidinone-based inhibitor, AMG 232 (or KRT-232), was evaluated in a Phase I trial recruiting patients with wild-type p53 advanced cancers, including ER+ breast cancer (NCT01723020). This evidence concerns the gene TP53 and breast cancer.